Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Immunomodulatory Type II … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Immunomodulatory Type II Natural Killer T Lymphocytes in Health and Disease

Artikel i vetenskaplig tidskrift
Författare Sara Rhost
Sai Kiran Sedimbi
N. Kadri
Susanna Cardell
Publicerad i Scandinavian Journal of Immunology
Volym 76
Nummer/häfte 3
Sidor 246-255
ISSN 0300-9475
Publiceringsår 2012
Publicerad vid Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi
Sidor 246-255
Språk en
Länkar dx.doi.org/10.1111/j.1365-3083.2012...
Ämnesord invariant nkt cells, immune-response, tumor-immunity, ulcerative-colitis, antitumor-activity, self glycolipids, cross-regulation, virus-infection, cutting edge, recognition, rcelli s, 1993, journal of experimental medicine, v178, p1, llabona p, 1994, journal of experimental medicine, v180, p1171
Ämneskategorier Immunologi inom det medicinska området

Sammanfattning

Natural killer T (NKT) lymphocytes are a beta T cells activated by lipid-based ligands presented on the non-polymorphic CD1d-molecule. Type I NKT cells that carry an invariant Va14 (in the mouse) or Va24 (in humans) T cell receptor a-chain rearrangement have received significant attention for their involvement in a diversity of immune reactions. Their sister population, CD1d-restricted type II NKT cells, has been more difficult to study because of the lack of molecular markers that specify these cells. In the last few years, however, significant progress has been made, demonstrating that type II NKT cells have unique functions in immune responses to tumours and infections, in autoimmunity, obesity and graft-versus-host disease. Type II NKT cells appear more frequent than type I NKT cells in humans and accumulate in certain diseases such as ulcerative colitis, hepatitis and multiple myeloma. Recently, novel type II NKT cell ligands have been identified, and it is becoming clear that the type II NKT cell population may be oligoclonal. Here, we review the recent progress in the study of type II NKT cells, supporting the view that type II NKT cells may be attractive targets for immunotherapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?